Development and preliminary validation of a plate-based CB1/CB2 receptor functional assay

Area of Science:

• Pharmacology
• Molecular Biology
• Biochemistry

Background:

• Cannabinoid (CB) receptors are therapeutic targets for various conditions including pain, anxiety, and cancer.
• Cannabinoid agonists show antiproliferative effects against certain cancers in preclinical models.
• Understanding CB receptor ligand interactions is crucial for drug development.

Purpose of the Study:

• To develop and validate a novel plate-based assay for measuring CB1 and CB2 receptor internalization.
• To assess the assay's utility in determining functional binding activities (IC50) of antagonists.
• To evaluate the assay's applicability for screening complex biological matrices, such as plant extracts.

Main Methods:

• Development of a plate-based assay measuring intracellular levels of radiolabeled agonists [(3)H]Win55-212-2 (CB1) and [(3)H]CP55-940 (CB2) following receptor internalization.
• Validation of the assay using known CB receptor antagonists (AM251, AM281, AM630, AM6545) to determine IC50 values.
• Screening of plant extracts from the genus Zanthoxylum using the developed assay to identify CB1/CB2 receptor activity.

Main Results:

• The developed plate-based assay accurately measured CB1 and CB2 receptor internalization.
• Validated IC50 values for known antagonists were consistent with previously reported data.
• The assay successfully identified Zanthoxylum plant extracts with activity at CB1/CB2 receptors, demonstrating its utility for complex matrix screening.

Conclusions:

• A novel, validated plate-based assay enables the measurement of CB1/CB2 receptor internalization.
• This assay is suitable for determining the functional binding activity of cannabinoid receptor ligands.
• The assay can be effectively employed for screening complex mixtures, such as natural product extracts, for cannabinoid receptor activity.